AbCellera Biologics (ABCL) Cash from Investing Activities (2020 - 2026)

AbCellera Biologics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$25.1 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 416.08% year-over-year to -$25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.7 million (down 44.95% YoY) and the FY2025 annual result came in at $87.8 million, down 27.72% from the prior year.
• Cash from Investing Activities was -$25.1 million for Q1 2026 at AbCellera Biologics, down from $75.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $75.1 million in Q4 2025 and bottomed at -$282.0 million in Q3 2022.
• A 5-year average of -$22.9 million and a median of -$17.1 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1385.03% — and 2025, when it soared 886.7%.
• AbCellera Biologics' Cash from Investing Activities stood at -$17.1 million in 2022, then plunged by 42.55% to -$24.3 million in 2023, then surged by 246.79% to $35.7 million in 2024, then soared by 110.45% to $75.1 million in 2025, then sank by 133.38% to -$25.1 million in 2026.
• Business Quant data shows ABCL's Cash from Investing Activities at -$25.1 million in Q1 2026, $75.1 million in Q4 2025, and $36.5 million in Q3 2025.